Claims for Patent: 12,201,614

Summary for Patent: 12,201,614

Title:	Methods for treating heterotopic ossification
Abstract:	The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
Inventor(s):	Clarissa Desjardins, Donna Roy GROGAN, Jeffrey Neal PACKMAN, Mark Harnett
Assignee:	Clementia Pharmaceuticals Inc
Application Number:	US18/758,242
Patent Claims:	1. A method of reducing heterotopic ossification in a subject with fibrodysplasia ossificans progressiva, said method comprising: (a) (i) during a period when the subject is not experiencing any flare-up symptom orally administering daily to the subject an amount of 5 mg of palovarotene, or a pharmaceutically acceptable salt thereof, and (ii) during a period when the subject is experiencing at least one flare-up symptom orally administering to the subject an amount of 20 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of 28 days, and after the period of 28 days, an amount of 10 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of at least 56 days; (b) determining that the subject is experiencing tolerance problems; and (c) reducing the dose of palovarotene administered to the subject. 2. The method of claim 1, wherein the daily dose of 20 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 15 mg palovarotene, or a pharmaceutically acceptable salt thereof. 3. The method of claim 1, wherein the daily dose of 10 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 7.5 mg palovarotene, or a pharmaceutically acceptable salt thereof. 4. The method of claim 1, wherein the daily dose of 20 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 15 mg palovarotene, or a pharmaceutically acceptable salt thereof; and the daily dose of 10 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 7.5 mg palovarotene, or a pharmaceutically acceptable salt thereof. 5. The method of claim 1, wherein step (c) of the method comprises: (i) during a period when the subject is not experiencing any flare-up symptom orally administering daily to the subject an amount of 5 mg of palovarotene, or a pharmaceutically acceptable salt thereof, and (ii) during a period when the subject is experiencing at least one flare-up symptom orally administering to the subject an amount of 15 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of 28 days, and after the period of 28 days, an amount of 10 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of at least 56 days. 6. The method of claim 1, wherein step (c) of the method comprises: (i) during a period when the subject is not experiencing any flare-up symptom orally administering daily to the subject an amount of 4 mg of palovarotene, or a pharmaceutically acceptable salt thereof, and (ii) during a period when the subject is experiencing at least one flare-up symptom orally administering to the subject an amount of 15 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of 28 days, and after the period of 28 days, an amount of 7.5 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of at least 56 days. 7. The method of claim 1, wherein step (c) of the method comprises: (i) during a period when the subject is not experiencing any flare-up symptom orally administering daily to the subject an amount of 5 mg of palovarotene, or a pharmaceutically acceptable salt thereof, and (ii) during a period when the subject is experiencing at least one flare-up symptom orally administering to the subject an amount of 10 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of 28 days, and after the period of 28 days, an amount of 10 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of at least 56 days. 8. A method of reducing heterotopic ossification in a subject with fibrodysplasia ossificans progressiva, wherein the subject weighs from 10 to 20 kg, said method comprising: (a) (i) during a period when the subject is not experiencing any flare-up symptom orally administering daily to the subject an amount of 2.5 mg of palovarotene, or a pharmaceutically acceptable salt thereof, and (ii) during a period when the subject is experiencing at least one flare-up symptom orally administering to the subject an amount of 10 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of 28 days, and after the period of 28 days, an amount of 5 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of at least 56 days; (b) determining that the subject is experiencing tolerance problems; and (c) reducing the dose of palovarotene administered to the subject. 9. The method of claim 8, wherein the daily dose of 2.5 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 1 mg palovarotene, or a pharmaceutically acceptable salt thereof; or the daily dose of 10 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 7.5 mg palovarotene, or a pharmaceutically acceptable salt thereof; or the daily dose of 5 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 3 mg palovarotene, or a pharmaceutically acceptable salt thereof. 10. The method of claim 8, wherein the daily dose of 2.5 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 1 mg palovarotene, or a pharmaceutically acceptable salt thereof; and the daily dose of 10 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 7.5 mg palovarotene, or a pharmaceutically acceptable salt thereof. 11. The method of claim 8, wherein the daily dose of 2.5 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 1 mg palovarotene, or a pharmaceutically acceptable salt thereof; and the daily dose of 10 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 7.5 mg palovarotene, or a pharmaceutically acceptable salt thereof; and the daily dose of 5 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 3 mg palovarotene, or a pharmaceutically acceptable salt thereof. 12. A method of reducing heterotopic ossification in a subject with fibrodysplasia ossificans progressiva, wherein the subject weighs from 20 to 40 kg, said method comprising: (a) (i) during a period when the subject is not experiencing any flare-up symptom orally administering daily to the subject an amount of 3 mg of palovarotene, or a pharmaceutically acceptable salt thereof, and (ii) during a period when the subject is experiencing at least one flare-up symptom orally administering to the subject an amount of 12.5 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of 28 days, and after the period of 28 days, an amount of 6 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of at least 56 days; (b) determining that the subject is experiencing tolerance problems; and (c) reducing the dose of palovarotene administered to the subject. 13. The method of claim 12, wherein the daily dose of 3 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 2.5 mg palovarotene, or a pharmaceutically acceptable salt thereof; or the daily dose of 12.5 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 10 mg palovarotene, or a pharmaceutically acceptable salt thereof; or the daily dose of 6 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 5 mg palovarotene, or a pharmaceutically acceptable salt thereof. 14. The method of claim 12, wherein the daily dose of 3 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 2.5 mg palovarotene, or a pharmaceutically acceptable salt thereof; and the daily dose of 12.5 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 10 mg palovarotene, or a pharmaceutically acceptable salt thereof; and the daily dose of 6 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 5 mg palovarotene, or a pharmaceutically acceptable salt thereof. 15. A method of reducing heterotopic ossification in a subject with fibrodysplasia ossificans progressiva, wherein the subject weighs from 40 to 60 kg, said method comprising: (a) (i) during a period when the subject is not experiencing any flare-up symptom orally administering daily to the subject an amount of 4 mg of palovarotene, or a pharmaceutically acceptable salt thereof, and (ii) during a period when the subject is experiencing at least one flare-up symptom orally administering to the subject an amount of 15 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of 28 days, and after the period of 28 days, an amount of 7.5 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of at least 56 days; (b) determining that the subject is experiencing tolerance problems; and (c) reducing the dose of palovarotene administered to the subject. 16. The method of claim 15, wherein the daily dose of 4 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 3 mg palovarotene, or a pharmaceutically acceptable salt thereof; or the daily dose of 15 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 12.5 mg palovarotene, or a pharmaceutically acceptable salt thereof; or the daily dose of 7.5 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 6 mg palovarotene, or a pharmaceutically acceptable salt thereof. 17. The method of claim 15, wherein the daily dose of 4 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 3 mg palovarotene, or a pharmaceutically acceptable salt thereof; and the daily dose of 15 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 12.5 mg palovarotene, or a pharmaceutically acceptable salt thereof; and the daily dose of 7.5 mg palovarotene, or a pharmaceutically acceptable salt thereof, is reduced to a daily dose of 6 mg palovarotene, or a pharmaceutically acceptable salt thereof. 18. The method of claim 1, wherein the 10 mg amount is administered daily for a period of 84 days. 19. The method of claim 1, wherein the 10 mg amount is administered daily for a period of 56 days. 20. The method of claim 1, wherein the at least one flare-up symptom is chosen from swelling, pain, erythema, warmth, stiffness, and decreased range of motion. 21. The method of claim 1, wherein the subject weighs greater than 60 kg. 22. The method of claim 8, wherein the 5 mg amount is administered daily for a period of 84 days. 23. The method of claim 8, wherein the 5 mg amount is administered daily for a period of 56 days. 24. The method of claim 8, wherein the at least one flare-up symptom is chosen from swelling, pain, erythema, warmth, stiffness, and decreased range of motion. 25. The method of claim 12, wherein the 6 mg amount is administered daily for a period of 84 days. 26. The method of claim 12, wherein the 6 mg amount is administered daily for a period of 56 days. 27. The method of claim 12, wherein the at least one flare-up symptom is chosen from swelling, pain, erythema, warmth, stiffness, and decreased range of motion. 28. The method of claim 15, wherein the 7.5 mg amount is administered daily for a period of 84 days. 29. The method of claim 15, wherein the 7.5 mg amount is administered daily for a period of 56 days. 30. The method of claim 15, wherein the at least one flare-up symptom is chosen from swelling, pain, erythema, warmth, stiffness, and decreased range of motion.